A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors - Concepedia

Concepedia

Publication | Closed Access

A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors

95

Citations

25

References

2006

Year

M. Basche, Daniel L. Gustafson, Scott N. Holden, Cindy L. O’Bryant, Lia Gore, Samir E. Witta, Mary Kay Schultz, Mark Morrow, Adrah Levin, Brian R. Creese,

Clinical Cancer Research

Abstract

The recommended dose of PI-88 administered for 4 consecutive days bimonthly or weekly is 250 mg/d. PI-88 was generally well tolerated. Evidence of efficacy in melanoma supports further evaluation of PI-88 in phase II trials.

References

	Year	Citations

Page 1